[The neuronal level of motor activity: determination of motor cortex excitability by TMS].
Transcranial magnetic stimulation as mapping method offers the possibility to measure aspects of motor cortex excitability painlessly and non-invasively. Using this neurophysiological tool, new insights into the effects of central-acting drugs are possible. Particularly striking seems to be the potential of this approach to gain new insights into neurobiological processes associated with neuropsychiatric diseases like schizophrenia or major depression. In combination with genetic aspects, TMS is able to bridge the gap between molecular research and clinical approach.
Eichhammer
Peter
P
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg. peter.eichhammer@medbo.de
Langguth
Berthold
B
Müller
Jürgen
J
Hajak
Göran
G
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001931:Brain Mapping; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004292:Dominance, Cerebral / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000503:physiopathology*; D019054:Evoked Potentials, Motor / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008280:Magnetics; D009044:Motor Cortex / Q000187:drug effects* / Q000503:physiopathology; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D011596:Psychomotor Disorders / Q000175:diagnosis / Q000503:physiopathology*; D018080:Receptors, GABA-B / Q000502:physiology; D012016:Reference Values; D015203:Reproducibility of Results; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012815:Signal Processing, Computer-Assisted
D014150:Antipsychotic Agents; D018080:Receptors, GABA-B